Palbociclib

Chemical formula: C₂₄H₂₉N₇O₂  Molecular mass: 447.533 g/mol  PubChem compound: 5330286

Therapeutic indications

Palbociclib is indicated for:

Breast cancer hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative

Population group: only adults (18 - 65 years old)

Palbociclib is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:

  • in combination with an aromatase inhibitor;
  • in combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Palbociclib is contraindicated in the following cases:

St. John's Wort

Hypericum perforatum (St John's Wort)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: IBRANCE Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈